2024
DOI: 10.7759/cureus.53654
|View full text |Cite
|
Sign up to set email alerts
|

Temporal Dynamics and Genomic Landscape of SARS-CoV-2 After Four Years of Evolution

Abdelmounim Essabbar,
Safae El Mazouri,
Nassma Boumajdi
et al.

Abstract: Introduction Since its emergence, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone extensive genomic evolution, impacting public health policies, diagnosis, medication, and vaccine development. This study leverages advanced bioinformatics to assess the virus’s temporal and regional genomic evolution from December 2019 to October 2023. Methods Our analysis incorporates 16,575 complete SARS-CoV-2 sequences collected from 214 countries. These samples were… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 31 publications
0
1
0
Order By: Relevance
“…This approach will allow us to forecast future epidemiological scenarios related to the emergence of unknown variants and their potential impact on the effectiveness of currently available vaccines that need to be re-engineered over time [ 14 ]. It may also provide additional data on potential genetic signatures and evolutionary trajectories of certain lineages showing altered antigenic properties, increased transmissibility, and higher disease severity [ 52 ].…”
Section: Discussionmentioning
confidence: 99%
“…This approach will allow us to forecast future epidemiological scenarios related to the emergence of unknown variants and their potential impact on the effectiveness of currently available vaccines that need to be re-engineered over time [ 14 ]. It may also provide additional data on potential genetic signatures and evolutionary trajectories of certain lineages showing altered antigenic properties, increased transmissibility, and higher disease severity [ 52 ].…”
Section: Discussionmentioning
confidence: 99%